Actively Recruiting
Study Comparing Maintenance Pegylated Liposomal Doxorubicin Treatment to Active Surveillance in Adults with Advanced Soft Tissue Sarcoma After Anthracycline Therapy
Led by National Health Research Institutes, Taiwan · Updated on 2026-07-02
81
Participants Needed
7
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to compare maintenance treatment with pegylated liposomal doxorubicin PLD versus active surveillance in patients with advanced soft tissue sarcoma whose disease is controlled after standard anthracycline-based chemotherapy. The trial evaluates whether continuing PLD can impact progression-free survival, overall survival, and quality of life in this patient group. It is a phase 2, randomized study sponsored by the National Health Research Institutes, Taiwan. Participants will be randomized into two groups. One group receives PLD at a dose of 40 mgm2 every 4 weeks for up to 12 cycles as maintenance therapy. The other group undergoes active surveillance without treatment, referred to as a treatment holiday crossover to PLD is not allowed after disease progression in this group. The study uses a parallel design to compare these two approaches. Participants will be monitored for up to approximately 2 years after randomization. Researchers will assess progression-free survival as the primary outcome, and secondary outcomes include overall survival, time to next treatment, response rates, and treatment safety including cardiac function. Quality of life will be assessed through patient-reported outcomes. The study includes regular assessments of organ function and adverse events, with careful monitoring throughout the study period.
CONDITIONS
Brief Title
Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)
Research Team
H
Hui-Jen Tsai, MD
T
Tom Wei-Wu Chen, MD,PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here